The decision is complex because (1) the efficacy of these drugs in preventing breast cancer is limited to estrogen receptor–positive tumors, (2) there is an increased risk of developing serious medical conditions with the use of these drugs, and (3) the recommendations are different for pre- and postmenopausal women [5,12]. The gene discussed is ESR1; the disease is breast carcinoma.